Skip to content
Doseworth
Menu

FDA warning letter · #716506

Healthy Male: What the FDA Letter Means for What You Pay

Activetirzepatide
Status

Operating

Concerns

marketing / labeling

Issued

September 2025

Response logged

Not logged

By Marla Whitfield, Pricing Editor

Primary source

Read the original letter on fda.gov →

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/healthy-male-716506-09092025

What FDA cited

Quoted verbatim from the letter dated

Read the full letter →

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthymale.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.

  1. 1

    "Clinically shown to support 15-22% average body weight reduction."

  2. 2

    "Clinically proven medications and compounds for sustainable weight management" "Clinically proven to deliver sustainable results…."

  3. 3

    Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.

Process

How a warning letter proceeds

  1. 1

    Letter issued

    September 2025

  2. 2

    15-working-day response window

    FDA gives the company 15 working days to respond in writing.

  3. 3

    Close-out, if issued

    FDA may post one once it is satisfied the cited issues have been corrected.

Is Healthy Male still operating?

healthymale.com resolved and returned a live storefront when we checked in August 2026, with a weight-loss category still listed among a broad men's-health catalogue built mainly around erectile dysfunction and testosterone support.

What this means for what you pay

A percentage is the most persuasive thing a weight-loss page can put next to a price, and it is also the easiest thing to borrow. FDA's objection here was not that the 15-22% figure is invented — trial results in that range exist for the approved tirzepatide product — but that presenting it as what this compounded product is "clinically shown" to do implies an evidence base and an FDA review the compounded product has not had. If you are weighing a monthly cost against an expected result, the cost is a fact about the seller and the percentage is a fact about somebody else's clinical trial. This letter is FDA saying the two should not be presented as one.

Has Healthy Male responded?

As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Healthy Male failed to respond.

Sources

Other letters in this index

View the full index →

Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.